



**KOLINPHARMA®**  
LEADER TO HEALTH

***KOLINPHARMA®: published the Notice of Italian Stock Exchange concerning the admission to trading on AIM Italia market.***

***First trading day scheduled on March 9<sup>th</sup>, 2018***

***Capital raised equal to € 3.1 million***

***Milan, March 8<sup>th</sup> 2018***

***KOLINPHARMA® SPA, Innovative SME operating in nutraceutical sector, informs that the Notice of the Italian Stock Exchange concerning the admission to trading of the ordinary actions on AIM Italia/Alternative Capital Market, multilateral trading system, organised and managed by Borsa Italiana S.p.A. was published.***

***The start date of trading is scheduled on March 9<sup>th</sup>, 2018.***

#### ***KOLINPHARMA® Profile***

***Kolinpharma®, founded in 2013, is an Innovative SME operating in nutraceutical sector and specialised in the research and development, realised internally and in collaboration with the major Italian universities. The Company's products are made with innovative and natural raw materials and they have the purpose of supporting the pharmacological treatments mainly for diseases in the orthopaedic-physiatric and urological-gynaecological fields. KOLINPHARMA® distributes the products with its brand all over the Italian territory, through a skilled network of 63 medical-scientific representatives (MSRs). The specialist doctors are professional directly contacted by the sales representatives' network. KOLINPHARMA's clients are represented by the wholesalers, who distribute to pharmacies and para-pharmacies in Italy.***

***In FY 2017 KOLINPHARMA® realised a turnover of Euro 4.1 million, growing over 60% compared to 2016, and an EBITDA margin of 15% (10% in 2016). The net financial indebtedness registered at the end of FY 2017 is about Euro 2.5 million.***

#### ***Placement***

***The equivalent value of the resources collected through the shares placement is Euro 3.1 million. The admission to the listing took place after the placement of 447,000 Kolinpharma ordinary shares newly issued and without nominal value. The unit price of the shares coming from the placement was fixed in Euro 7.0 per share (of which Euro 1.0 nominal value and Euro 6.0 share-premium); on the base of this price, market capitalization is expected equal to Euro 10.2 million. The market float of the transaction after listing will be 31.65% (the market float does not include the Price Adjustment Shares) of the share capital. The minimum lot is fixed in 200 shares.***



**KOLINPHARMA®**

LEADER TO HEALTH

### **Price Adjustment Shares**

At the beginning of trading on AIM Italia, the founders will be owner of n. 180,000 Price Adjustment Shares (PAS). These shares, in case of failure to achieve some Company's profitability targets for fiscal years closed on December 31<sup>st</sup> 2017 and 2018 (i.e. EBITDA higher than Euro 500,000 and EBITDA higher than Euro 1,400,000 respectively), will be - totally or in part – cancelled, hence determining a reduction of the number of Company's shares held by founding shareholders and, consequently, the capital share held by others shareholders will increase. Vice versa, in case of achieving the above-mentioned profitability targets, PAS will be converted - totally or in part – into ordinary shares KOLINPHARMA. For more information about PAS, please refer to the Admission Document that will be published on the Company's website ([www.kolinpharma.com](http://www.kolinpharma.com)), in the Investor Relations section.

### **Share capital and shareholding**

After placement, KOLINPHARMA® share capital is equal to Euro 1,639,571, made up of 1,639,571 shares without nominal value, whereof 1,459,572 are ordinary shares and 180,000 are Price Adjustment Shares.

The shareholding composition as results of the placement will be the following one:

SHAREHOLDER	N° OF SHARES	% IN SHARE CAPITAL
Rita Paola Petrelli	862,571	52.61%
Emanuele Lusenti	315,000	19.21%
Anna Laura Lanza	10,000	0.61%
Carminé di Vincenzo	5,000	0.30%
Market	447,000	27.26%
<b>Total</b>	<b>1,639,571</b>	<b>100.00%</b>

Founding shareholders, Rita Paola Petrelli (Kolinpharma's Chairwoman and CFO) and Emanuele Lusenti (CEO), and the company took some lock-up commitments containing prohibitions of arrangements of the held shares for a period of 24 months starting from the beginning of trading.

Italian Stock Exchange attributed to Kolinpharma the following identification code:

- Alphanumeric Code: KIP (ordinary shares)

ISIN code assigned to the ordinary shares is the following one:

- IT0005322950

### **Other information**

During the listing process Kolinpharma was helped by the following consultants: EnVent Capital Markets Ltd. (Nominated Adviser and Global Coordinator) assisted by Pedersoli Studio Legale, Emintad, Lombarda & Associati and IR Top Consulting (Financial Advisor), Studio Legale Ughi e Nunziante (Legal Advisor of the Issuer), BDO Italia S.p.A. (auditing firm). Directa SIM S.p.A. acted as online retailer distributor.



KOLINPHARMA®

LEADER TO HEALTH

The Admission Document is available at the registered office of the Company and in the Investor Relations section of the website [www.kolinpharma.com](http://www.kolinpharma.com).

It is also declared that for the transmission and storage of Regulated Information Kolinpharma uses the eMarket SDIR distribution system and the eMarket STORAGE storage mechanism, available at [www.emarketstorage.com](http://www.emarketstorage.com) and managed by Spafid Connect S.p.A..

Documents related to the transaction will be also made available on PMI Capital, digital information platform entirely dedicated to the AIM Italia market and to institutional and professional investors.

This press release is available online on our corporate website [www.kolinpharma.com](http://www.kolinpharma.com), in the section Investor Relations > Financial Press Releases.

\*\*\*

KOLINPHARMA® S.p.A., founded in 2013, is an Innovative SME operating in nutraceutical sector and specialised in the research and development, realised internally and in collaboration with the major Italian universities. The Company's products are made of innovative and natural raw materials and have the purpose of supporting the pharmacological treatments mainly for the diseases in the orthopaedic-physiatric and gynaecological fields. KOLINPHARMA distributes the products with its brand in the whole Italian territory through a skilled sales network of 63 medical-scientific representatives (MSRs), specialised sole agents graduated in scientific disciplines. The MSRs promote KOLINPHARMA's nutraceutical products directly to doctors, pointing at the specialists' awareness. The Company's direct clients are wholesalers, that distribute to pharmacies and para-pharmacies throughout Italy. KOLINPHARMA owns 4 patents in Italy and 9 certifications, of which 2 on the company and 7 on its products.

#### Contacts

IR TOP Consulting S.r.l.  
Capital Markets & Investor Relations  
Floriana Vitale, Domenico Gentile  
[f.vitale@irtop.com](mailto:f.vitale@irtop.com), [d.gentile@irtop.com](mailto:d.gentile@irtop.com)  
Via C. Cantù, 1 - 20123 Milan  
Tel.: +39 02 4547 3883/4

EnVent Capital Markets Ltd.  
Nominated Adviser (NOMAD)  
Francesca Martino  
[fmartino@enventcapitalmarkets.co.uk](mailto:fmartino@enventcapitalmarkets.co.uk)  
42 Berkeley Square - London W1J 5AW Italian  
Branch, via Barberini n. 95 - 00187 Rome  
Tel.: +39 06 896841 Fax: +39 06 89684155

